79 related articles for article (PubMed ID: 18729)
1. Unwanted effects of psychotrophic drugs. II.--Drugs for schizophrenia.
Edwards JG
Practitioner; 1977 May; 218(1307):696-700. PubMed ID: 18729
[No Abstract] [Full Text] [Related]
2. Antipsychotic drugs--an update.
Charalampous KD; Keepers GA
J Okla State Med Assoc; 1978 Jan; 71(1):6-9. PubMed ID: 23420
[No Abstract] [Full Text] [Related]
3. Prolactin response and extrapyramidal side effects during propranolol and neuroleptic drugs treatment in chronic schizophrenic patients.
Elizur A; Segal S; Yeret A; Ben-David M
Isr Ann Psychiatr Relat Discip; 1979 Dec; 17(4):318-27. PubMed ID: 44877
[No Abstract] [Full Text] [Related]
4. [A practical guide for the use of psychopharmacologic agents. II. Antipsychotic and antiparkinson agents].
Chouinard G
Union Med Can; 1976 Sep; 105(9):1387-97. PubMed ID: 9720
[No Abstract] [Full Text] [Related]
5. Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models.
Casey DE
Br J Psychiatry Suppl; 1996 May; (29):32-9. PubMed ID: 8733821
[No Abstract] [Full Text] [Related]
6. Use of novel antipsychotic drugs.
Raleigh F
Pharmacotherapy; 1996; 16(6 Pt 2):160S-165S; discussion 166S-168S. PubMed ID: 8948000
[TBL] [Abstract][Full Text] [Related]
7. Atypical antipsychotics in the treatment of schizophrenia. Paper underrates patients' experience of extrapyramidal symptoms.
Kerwin R
BMJ; 2001 Apr; 322(7291):926-7; author reply 927-8. PubMed ID: 11302914
[No Abstract] [Full Text] [Related]
8. [Schizophrenia: adverse effects of atypical neuroleptics].
Bettina Polk B
Med Monatsschr Pharm; 2003 Feb; 26(2):57-9. PubMed ID: 12619525
[No Abstract] [Full Text] [Related]
9. Medical and legal implications of side effects from neuroleptic drugs. A round-table discussion.
Cancro R; Davis JM; Klawans H; Tancredi L
J Clin Psychiatry; 1981 Feb; 42(2):78-82. PubMed ID: 6109720
[TBL] [Abstract][Full Text] [Related]
10. Choosing an atypical antipsychotic.
Sussman N
Int Clin Psychopharmacol; 2002 Aug; 17 Suppl 3():S29-33. PubMed ID: 12570069
[TBL] [Abstract][Full Text] [Related]
11. A long-term pilot study of pipothiazine palmitate in chronic schizophrenia.
Villeneuve A; Pires A; Jus A; Lachance R; Drolet A
Curr Ther Res Clin Exp; 1972 Nov; 14(11):696-706. PubMed ID: 4404626
[No Abstract] [Full Text] [Related]
12. [Treatment of schizophrenia].
Houy-Durand E; Thibaut F
Rev Prat; 2002 Jun; 52(11):1213-20. PubMed ID: 12148207
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics in the treatment of schizophrenia. Users' views are important.
Anderson I
BMJ; 2001 Apr; 322(7291):926; author reply 927-8. PubMed ID: 11302919
[No Abstract] [Full Text] [Related]
14. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Leucht S; Kissling W; Davis JM
Psychol Med; 2009 Oct; 39(10):1591-602. PubMed ID: 19335931
[TBL] [Abstract][Full Text] [Related]
15. The management of schizophrenia.
Bennett DH
Br J Psychiatry; 1975; Spec No 9():48-54. PubMed ID: 241452
[No Abstract] [Full Text] [Related]
16. [From neuroleptics toward antipsychotics: practice of changing the treatment, choice of the time and disputes, clinical aspects].
Plas J
Encephale; 2003 Sep; 29(Pt 2):S40-2. PubMed ID: 14710536
[No Abstract] [Full Text] [Related]
17. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
Möller HJ; Kissling W
Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841
[No Abstract] [Full Text] [Related]
18. Assessing negative symptoms and extrapyramidal symptoms in schizophrenia: workshop report.
Kane JM; Dauphinais D; Barnes TR; Adler LA; Rifkin A
Psychopharmacol Bull; 1993; 29(1):45-9. PubMed ID: 8104351
[No Abstract] [Full Text] [Related]
19. [Risperidone].
Zolk O; Thürauf N
Dtsch Med Wochenschr; 2003 Jun; 128(24):1353-6. PubMed ID: 12802745
[No Abstract] [Full Text] [Related]
20. [Neuroleptics and the extrapyramidal system].
Haase HJ
Arzneimittelforschung; 1978; 28(9):1536-7. PubMed ID: 38814
[No Abstract] [Full Text] [Related]
[Next] [New Search]
